Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults

Deposition of hyperphosphorylated tau protein is observed in several neurodegenerative
diseases including Alzheimer's Disease (AD), progressive supranuclear palsy, corticobasal
degeneration, chronic traumatic encephalopathy, and frontotemporal lobar degeneration. Tau is
a microtubular protein and its native function is to provide structural support to neurons.
Paired helical filaments composed of dysfunctional tau protein are found in several
neurodegenerative diseases. In AD, the clinical progression of dementia has been shown to
correlate with the amount and topographical spread of tau throughout the brain. Therefore,
detecting and quantifying tau aggregate load in brain would have diagnostic and prognostic
potential in clinical management of several neurological diseases. As disease modifying drugs
that target tau are being developed, there is a critical need for a reliable method of
detecting tau aggregates to confirm pathology in patients entering clinical trials.

Inclusion Criteria:

- Aged 55 - 75 years

- Are undergoing a structural MRI scan as a part of the Offspring Study

- Have either mild cognitive impairment or mild clinical Alzheimer's disease; or have no
problem with memory or thinking.

- Able to participate in all scheduled evaluations and to complete all required tests
and procedures

- Considered likely to comply with the study protocol and to have a high probability of
completing the study

Exclusion Criteria:

- Past or present history of a certain brain disease other than mild cognitive
impairment or mild clinical Alzheimer's disease.

- Certain significant medical conditions. Examples are uncontrolled epilepsy or multiple
serious injuries.

- Unable to lie still for PET scans.

- Radiation exposure for research studies in the last year that would put you past
allowable limits if included in this study.

- Participation in the last year in a clinical trial for a disease modifying drug for AD
unless it can be determined that your received placebo and not active drug.

- Conditions that preclude entry into the scanner (e.g. claustrophobia, etc.).

- Inability to have a catheter in your vein for the injection of the radioligand (dye).

- Currently pregnant or breastfeeding.